Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Incorporating Real-World Evidence into Clinical Decisions in NSCLC
October 21st 2021Lyudmila Bazhenova, MD, and Frederico Albrecht, MD, consider when to refer to a clinical trial data and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on a recent publication by Bassel Nazha, MD, MPH.
Circulating Tumor DNA as a Biomarker of Progression in Colorectal Cancer
October 8th 2021Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” and consider how to apply the paper’s findings into clinical practice.
Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
August 20th 2021In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.
Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box
August 9th 2021In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.